Impact of tuberculosis treatment on CD4 cell count, HIV RNA, and p24 antigen in patients with HIV and tuberculosis

Int J Infect Dis. 2013 Oct;17(10):e907-12. doi: 10.1016/j.ijid.2013.05.003. Epub 2013 Jun 28.

Abstract

Objectives: To describe HIV RNA levels during tuberculosis (TB) infection in patients co-infected with TB and HIV. Moreover, to examine the p24 antigen profile during TB treatment.

Methods: We examined the changes in CD4 cell count, HIV RNA, and p24 levels during anti-tuberculous therapy in a group of TB/HIV-1 co-infected and HIV-untreated patients from Guinea-Bissau.

Results: A total of 365 TB patients were enrolled, of whom 76 were co-infected with HIV-1 and 19 were dually infected with HIV-1 + HIV-2. No significant changes in CD4, HIV RNA, or p24 levels were found during 8 months of TB treatment. HIV RNA levels correlated well with p24 (Spearman's R(2)=0.52, p<0.00001) and both markers were strong predictors of mortality. Initial HIV RNA levels correlated with a clinical TB severity index--the TBscore (Spearman's R(2)=0.23, p=0.02)--and the TBscore decreased dramatically during TB treatment although HIV RNA levels remained unchanged.

Conclusion: We found no significant changes in CD4, HIV RNA, or p24 antigen levels during 8 months of TB treatment among TB/HIV co-infected individuals, who did not receive antiretroviral treatment. The markers were unaffected by a strong improvement in TBscore and all three markers showed predictive capacity for mortality risk.

Keywords: CD4 count; Clinical score; HIV RNA; Tuberculosis; p24 antigen.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antitubercular Agents / pharmacology*
  • Antitubercular Agents / therapeutic use
  • Biomarkers / blood
  • CD4 Lymphocyte Count
  • Coinfection / blood
  • Coinfection / immunology*
  • Coinfection / mortality
  • Dietary Supplements
  • Drug Therapy, Combination
  • Ethambutol / pharmacology
  • Ethambutol / therapeutic use
  • Female
  • Guinea-Bissau
  • HIV Core Protein p24 / blood
  • HIV Infections / blood
  • HIV Infections / immunology*
  • HIV Infections / mortality
  • HIV-1 / immunology*
  • HIV-2 / immunology*
  • Humans
  • Isoniazid / pharmacology
  • Isoniazid / therapeutic use
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Pyrazinamide / pharmacology
  • Pyrazinamide / therapeutic use
  • RNA, Viral
  • Rifampin / pharmacology
  • Rifampin / therapeutic use
  • Tuberculosis, Pulmonary / blood
  • Tuberculosis, Pulmonary / drug therapy*
  • Tuberculosis, Pulmonary / immunology
  • Tuberculosis, Pulmonary / mortality
  • Vitamin D / administration & dosage
  • Young Adult

Substances

  • Antitubercular Agents
  • Biomarkers
  • HIV Core Protein p24
  • RNA, Viral
  • Vitamin D
  • Pyrazinamide
  • Ethambutol
  • Isoniazid
  • Rifampin